What's more, any new strains we do see spreading more widely will do so because their mutations confer a competitive advantage. In practice that usually means more drift towards higher infectiousness but less severe symptoms - the same mechanisms that have left us with 4 other endemic but mild common cold coroanviruses.
The new SARS-COV-2 vaccines may be a useful tool to get us over this hump where the virus is still novel to a large proportion of the population, but are unlikely to be required indefinitely.
This is why OP is asking and mentioning the minks in Denmark.
Regardless of whether the mutations are significant enough to affect vaccine efficacy, it won't likely be a problem. These new mRNA vaccines have a development/production time measured in weeks and months, not years. It changes vaccines from a hardware problem to a software problem. Once the underlying delivery technology is proven safe and effective, reacting to new strains will be as swift as patching a codebase. It's hard to overstate what a massive advance in vaccine tech is happening here.
https://www.nature.com/articles/nrd.2017.243
The basic idea is that now rather than needing to culture live viruses in chicken eggs, we can literally just encode the RNA for a specific antigen into a synthetic substrate and produce vaccines through a chemical process like any other drug. The RNA is then absorbed into your cells, and your own body creates the proteins which stimulate an immune response.
So I think it's somewhat likely that we'll see mutations emerge all over the world.
Whether this vaccine works depends on how early we get most people vaccinated. It may only be a short term patch, which we will see once it's rolled out, you can't really predict the long term without any measurements.
We have seen mutations due to minks recently which could make the vaccinations ineffective. These mutations might have been controlled but similar situations may arise in the next years.
For these reasons I am not entirely sure this is the beginning of the end.